Sunday, 09 August 2020

Baring Private Equity Asia to acquire Lumenis

21 November 2019 | News

Lumenis is a global leader in the field of minimally-invasive clinical solutions for the Aesthetic, Surgical, and Ophthalmology specialties

Baring Private Equity Asia (BPEA) has announced that its affiliated private equity funds have agreed to acquire Lumenis, a leading provider of specialty energy-based medical devices across the fields of aesthetics, urology, ophthalmology, ENT and gynecology from XIO. The transaction values Lumenis at an enterprise value of over $1 billion.

Lumenis is a global leader in the field of minimally-invasive clinical solutions for the Aesthetic, Surgical, and Ophthalmology specialties. For over 50 years, Lumenis' ground-breaking products have redefined medical treatments and have set numerous gold-standards. The company has a presence in over 100 countries and close to 1,500 employees worldwide. The Asia Pacific region is its largest market, together with a strong presence in North America and EMEA.

"BPEA's investment is a tremendous vote of confidence in Lumenis and in the achievements of our entire global organization. In recent years, we have developed and introduced multiple groundbreaking technological solutions that have redefined our industry and opened entirely new market segments. I would like to thank the entire Lumenis team, I am truly proud of all we have accomplished and honored to lead a company on the cutting edge of healthcare innovation, committed to improving the lives of people across the world. We look forward to partnering with the team at BPEA to continue developing and delivering to the world better technology for better patient care," said Tzipi Ozer-Armon, CEO of Lumenis. 

Yan Jiao, Managing Director at BPEA commented: "Lumenis has built a market-leading position by creating some of the most innovative technologies in the industry. It is a clear leader worldwide, especially in Asia which recently emerged as the largest market for medical and aesthetics treatments. We look forward to working with the CEO and management team to support their global growth aspirations."

The transaction remains subject to the customary regulatory approval process and is expected to be completed in early 2020.


Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Survey Box

Should we be cautious of viewing COVID-19 vaccine as silver bullet?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls